Temocapril HCl
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Category
- Other Pharmaceuticals
Inist ST
South Korea
- Verified Certificate
-
16
| Product name | Temocapril HCl | Certification | - |
|---|---|---|---|
| Category | Other Pharmaceuticals | Ingredients | - |
| Keyword | active pharmaceutical ingredient , api , temocapril hcl | Unit Size | - |
| Brand name | - | Unit Weigh | - |
| origin | South Korea | Stock | - |
| Supply type | - | HS code | - |
Product Information
Temocapril HCl
| Category |
Antihypertensive
| Spec |
JP / IHS
| Description |
Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor approved in Japan and South Korea. & also be used in hemodialysis patients without risk of serious accumulation.
this compound inhibits ACE (angiotensin-converting enzyme), which catalyzes the conversion of angiotensin I to angiotensin II by cleaving a dipeptide from the C-terminus. Angiotensin II binds to angiotensin II receptors, causing vasoconstriction and an increase in bloodpressure. Furthermore, the binding of angiotensin II causes the release of aldosterone, which causes reabsorption of water and sodium in the distal tubule.
B2B Trade
| Price (FOB) | Negotiable | transportation | - |
|---|---|---|---|
| MOQ | Negotiable | Leadtime | Negotiable |
| Payment Options | Negotiable | Shipping time | Negotiable |
- President
- Kim Kuk-hyun
- Address
- Geumwang-Eup, 500 Shinaero , Eumseong-gun, Chungcheongbuk-do, Korea
- Product Category
- Pharmaceuticals
- Year Established
- 2000
- Company introduction
-
Having persistent enthusiasm, INIST ST is trying to contribute to the society and community by delivering healthier life from age 0 to 110 years through research and innovation. Since its establishment in 2000, INIST ST has been accomplishing rapid growth with passion, confidence and trust between customers and the company. INIST ST has developed non-cytotoxic anti-cancer, high quality generic & value-added API and supplied to the domestic and overseas markets. INIST ST has intensive R&D function in exploration of drug candidate and process development of small molecules. As result of those efforts, INIST ST has achieved multiple crystal and process patents and become partner of several government sponsoring development projects.
- Main Markets
-
Japan
Taiwan
Turkey
U.S.A
- Main Product
Related Products
INIBO-Injection to reduce fine lines and wrinkles
Botalinum Ampoule
Elitox®
Daehan New Pharm Vitamin C injection
PPAEBAR Lactoferrin Dietary Supplement
